Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 6
2017 5
2018 8
2019 12
2020 3
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

32 results
Results by year
Filters applied: . Clear all
Page 1
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.
Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U. Lancaster LH, et al. Among authors: kirchgaessler ku. Eur Respir Rev. 2017 Dec 6;26(146):170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31. Eur Respir Rev. 2017. PMID: 29212837 Free article. Review.
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V. Maher TM, et al. Among authors: kirchgaessler ku. Lancet Respir Med. 2020 Feb;8(2):147-157. doi: 10.1016/S2213-2600(19)30341-8. Epub 2019 Sep 29. Lancet Respir Med. 2020. PMID: 31578169 Free article. Clinical Trial.
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Nathan SD, et al. Among authors: kirchgaessler ku. Lancet Respir Med. 2017 Jan;5(1):33-41. doi: 10.1016/S2213-2600(16)30326-5. Epub 2016 Nov 19. Lancet Respir Med. 2017. PMID: 27876247
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J, Nathan SD, Wuyts WA, Mogulkoc Bishop N, Bouros DE, Antoniou K, Guiot J, Kramer MR, Kirchgaessler KU, Bengus M, Gilberg F, Perjesi A, Harari S, Wells AU. Behr J, et al. Among authors: kirchgaessler ku. Lancet Respir Med. 2021 Jan;9(1):85-95. doi: 10.1016/S2213-2600(20)30356-8. Epub 2020 Aug 18. Lancet Respir Med. 2021. PMID: 32822614 Clinical Trial.
Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis.
Kreuter M, Lederer DJ, Cottin V, Kahn N, Ley B, Vancheri C, Weycker D, Atwood M, Kirchgaessler KU, Ryerson CJ. Kreuter M, et al. Among authors: kirchgaessler ku. Eur Respir J. 2019 Dec 12;54(6):1901188. doi: 10.1183/13993003.01188-2019. Print 2019 Dec. Eur Respir J. 2019. PMID: 31537696 Free PMC article.
Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis.
Kreuter M, Lederer DJ, Molina-Molina M, Noth I, Valenzuela C, Frankenstein L, Weycker D, Atwood M, Kirchgaessler KU, Cottin V. Kreuter M, et al. Among authors: kirchgaessler ku. Chest. 2019 Oct;156(4):706-714. doi: 10.1016/j.chest.2019.04.015. Epub 2019 Apr 29. Chest. 2019. PMID: 31047956 Free article. Clinical Trial.
Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis.
Costabel U, Albera C, Glassberg MK, Lancaster LH, Wuyts WA, Petzinger U, Gilberg F, Kirchgaessler KU, Noble PW. Costabel U, et al. Among authors: kirchgaessler ku. Respir Res. 2019 Mar 12;20(1):55. doi: 10.1186/s12931-019-1021-2. Respir Res. 2019. PMID: 30866942 Free PMC article. Clinical Trial.
32 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page